This page in English
Laddar profil information

Publikationer

Cardiovascular outcome in treatment-resistant hypertension: results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Holmqvist L, Boström Kb, Kahan T, Schiöler L, Hasselström J, Hjerpe P, et al
Journal of hypertension 2018;36(2):402-409

Drug adherence in treatment resistant and in controlled hypertension-Results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Holmqvist L, Boström Kb, Kahan T, Schiöler L, Qvarnström M, Wettermark B, et al
Pharmacoepidemiology and drug safety 2018;27(3):315-321

Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity
Wallentin F, Wettermark B, Kahan T
Journal of clinical hypertension (Greenwich, Conn.) 2018;20(1):106-114

Effectiveness of Drugs in Routine Care: A Model for Sequential Monitoring of New Medicines Using Dronedarone as Example
Cars T, Lindhagen L, Malmström Re, Neovius M, Schwieler J, Wettermark B, et al
Clinical pharmacology and therapeutics 2018;103(3):493-501

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
Frisk P, Aggefors K, Cars T, Feltelius N, Loov Sa, Wettermark B, et al
European journal of clinical pharmacology 2018;74(7):971-978

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
Eriksson I, Cars T, Piehl F, Malmström Re, Wettermark B, Von Euler M
European journal of clinical pharmacology 2018;74(2):219-226

Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
Forslund T, Wettermark B, Andersen M, Hjemdahl P
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2018;20(3):420-428

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
Eriksson I, Komen J, Piehl F, Malmström Re, Wettermark B, Von Euler M
European journal of clinical pharmacology 2018;74(5):663-670

Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses
Karlsson Lind L, Wide K, Wettermark B, Von Euler M
Basic & clinical pharmacology & toxicology 2018;123(1):94-100

Antibiotic use and bacterial complications following upper respiratory tract infections: a population-based study
Cars T, Eriksson I, Granath A, Wettermark B, Hellman J, Norman C, et al
BMJ open 2017;7(11):e016221-

Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease
Klatte Dcf, Gasparini A, Xu H, De Deco P, Trevisan M, Johansson Alv, et al
Gastroenterology 2017;153(3):702-710

Educational intervention on medication reviews aiming to reduce acute healthcare consumption in elderly patients with potentially inappropriate medicines-A pragmatic open-label cluster-randomized controlled trial in primary care
Schmidt-mende K, Andersen M, Wettermark B, Hasselström J
Pharmacoepidemiology and drug safety 2017;26(11):1347-1356

Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B
British journal of clinical pharmacology 2017;83(3):642-652

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
Komen J, Forslund T, Hjemdahl P, Wettermark B
European journal of clinical pharmacology 2017;73(10):1315-1322

Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study
Bergqvist J, Iderberg H, Mesterton J, Bengtsson N, Wettermark B, Henriksson R
Acta oncologica (Stockholm, Sweden) 2017;56(3):405-414

Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study
Brostedt Em, Msghina M, Persson M, Wettermark B
BMC psychiatry 2017;17(1):416-

HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY
Guerra-júnior Aa, Pires De Lemos Ll, Godman B, Bennie M, Osorio-de-castro Cgs, Alvares J, et al
International journal of technology assessment in health care 2017;33(2):279-287

High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines
Stockholm Dtc, Eriksen J, Gustafsson Ll, Ateva K, Bastholm-rahmner P, Ovesjö Ml, et al
BMJ open 2017;7(4):e014345-

Improved treatment and control of hypertension in Swedish primary care: results from the Swedish primary care cardiovascular database
Holmquist C, Hasselström J, Bengtsson Boström K, Manhem K, Wettermark B, Hjerpe P, et al
Journal of hypertension 2017;35(10):2102-2108

Non-steroidal anti-inflammatory drugs and blood pressure control in patients treated for hypertension: results from the Swedish primary care cardiovascular database
Ljungman C, Kahan T, Schiöler L, Wettermark B, Boström Kb, Hasselström J, et al
Blood pressure 2017;26(4):220-228

Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants
Loikas D, Forslund T, Wettermark B, Schenck-gustafsson K, Hjemdahl P, Von Euler M
The American journal of cardiology 2017;120(8):1302-1308

Sociodemographic factors are associated with utilisation of statins after ischaemic stroke/TIA
Geary L, Aronius J, Wettermark B, Hasselström J, Sjöborg B, Von Euler M
International journal of clinical practice 2017;71(3-4):-

The Early Awareness and Alert System in Sweden: History and Current Status
Eriksson I, Wettermark B, Persson M, Edström M, Godman B, Lindhé A, et al
Frontiers in pharmacology 2017;8():674-

Trends in medicines procurement by the Brazilian federal government from 2006 to 2013
Chama Borges Luz T, Garcia Serpa Osorio-de-castro C, Magarinos-torres R, Wettermark B
PloS one 2017;12(4):e0174616-

Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
Forslund T, Wettermark B, Hjemdahl P
European journal of clinical pharmacology 2016;72(3):329-38

Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies
Garuolienė K, Godman B, Gulbinovič J, Schiffers K, Wettermark B
Expert review of pharmacoeconomics & outcomes research 2016;16(2):149-52

Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease
Cars T, Wettermark B, Löfberg R, Eriksson I, Sundström J, Lördal M
Journal of Crohn's & colitis 2016;10(5):556-65

How to best assess quality of drug treatment in patients with heart failure
Zarrinkoub R, Kahan T, Johansson Se, Wändell P, Mejhert M, Wettermark B
European journal of clinical pharmacology 2016;72(8):965-75

Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence
Citarella A, Linder M, Kieler H, Berglind Ia, Sundström A, Wettermark B, et al
European journal of clinical pharmacology 2016;72(3):349-57

Medicine use and disease control among adolescents with asthma
Dahlén E, Wettermark B, Bergström A, Jonsson Ew, Almqvist C, Kull I
European journal of clinical pharmacology 2016;72(3):339-47

Neighborhood Socioeconomic Characteristics and Utilization of ADHD Medication in Schoolchildren: A Population Multilevel Study in Stockholm County
Jablonska B, Kosidou K, Ponce De Leon A, Wettermark B, Magnusson C, Dal H, et al
Journal of attention disorders 2016;():-

Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD)
Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Boström Kb, et al
Medicine 2016;95(40):e4908-

Prevalence and recognition of chronic kidney disease in Stockholm healthcare
Gasparini A, Evans M, Coresh J, Grams Me, Norin O, Qureshi Ar, et al
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016;31(12):2086-2094

Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database
Holmqvist L, Boström Kb, Kahan T, Schiöler L, Hasselström J, Hjerpe P, et al
Journal of the American Society of Hypertension : JASH 2016;10(11):838-846

The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature
Wallerstedt Sm, Wettermark B, Hoffmann M
Basic & clinical pharmacology & toxicology 2016;119(5):464-469

The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness
Runesson B, Gasparini A, Qureshi Ar, Norin O, Evans M, Barany P, et al
Clinical kidney journal 2016;9(1):119-27

Time trends in statin utilisation and coronary mortality in Western European countries
Vancheri F, Backlund L, Strender Le, Godman B, Wettermark B
BMJ open 2016;6(3):e010500-

Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden
Frisk P, Sporrong Sk, Ljunggren G, Wettermark B, Von Euler M
European journal of clinical pharmacology 2016;72(6):747-54

7B.02: THE ASSOCIATION BETWEEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS AND THE RELATION TO GENDER
Ljungman C, Kahan T, Schiöler L, Wettermark B, Boström Kb, Hasselström J, et al
Journal of hypertension 2015;33 Suppl 1():e92-

7B.10: THIAZIDE DIURETICS AND FRACTURE-RISK AMONG HYPERTENSIVE PATIENTS. RESULTS FROM THE SWEDISH PRIMARY CARE CARDIOVASCULAR DATABASE (SPCCD)
Bokrantz T, Ljungman C, Kahan T, Schioler L, Hjerpe P, Hasselstrom J, et al
Journal of hypertension 2015;33 Suppl 1():e94-5

Antihypertensive treatment and control according to gender, education, country of birth and psychiatric disorder: the Swedish Primary Care Cardiovascular Database (SPCCD)
Ljungman C, Kahan T, Schiöler L, Hjerpe P, Wettermark B, Boström Kb, et al
Journal of human hypertension 2015;29(6):385-93

Concomitant use of two or more antipsychotic drugs is common in Sweden
Bergendal A, Schiöler H, Wettermark B, Björkstén Ks
Therapeutic advances in psychopharmacology 2015;5(4):224-31

[More with atrial fibrillation, anticoagulants since the coming of NOAK ]
Forslund T, Von Euler M, Johnsson H, Holmström M, Wettermark B, Hjemdahl P
Lakartidningen 2015;112():-

Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe
Poluzzi E, Raschi E, Godman B, Koci A, Moretti U, Kalaba M, et al
PloS one 2015;10(3):e0119551-

Quality Indicators as a Tool in Improving the Introduction of New Medicines
Campbell Sm, Godman B, Diogene E, Furst J, Gustafsson Ll, Macbride-stewart S, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2015;116(2):146-57

The establishment and expansion of an innovative centre for rational pharmacotherapy-determinants and challenges
Kardakis T, Tomson G, Wettermark B, Brommels M, Godman B, Bastholm-rahmner P
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT 2015;30(1):14-30

Unexplained acute chest pain in young adults: disease patterns and medication use 25 years later
Roll M, Rosenqvist M, Sjöborg B, Wettermark B
Psychosomatic medicine 2015;77(5):567-74

Drug treatment in patients with newly diagnosed unprovoked seizures/epilepsy
Karlsson L, Wettermark B, Tomson T
Epilepsy research 2014;108(5):902-8

Factors associated with concordance between parental-reported use and dispensed asthma drugs in adolescents: findings from the BAMSE birth cohort
Dahlén E, Almqvist C, Bergström A, Wettermark B, Kull I
Pharmacoepidemiology and drug safety 2014;23(9):942-9

Factors associated with pregabalin dispensing at higher than the approved maximum dose
Bodén R, Wettermark B, Brandt L, Kieler H
European journal of clinical pharmacology 2014;70(2):197-204

Family history of cardiovascular disease and influence on statin therapy persistence
Citarella A, Kieler H, Sundström A, Linder M, Wettermark B, Berglind Ia, et al
European journal of clinical pharmacology 2014;70(6):701-7

Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B, et al
Journal of the American Society of Hypertension : JASH 2014;8(12):882-90

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
Godman B, Wettermark B, Van Woerkom M, Fraeyman J, Alvarez-madrazo S, Berg C, et al
Frontiers in pharmacology 2014;5():106-

Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment
Wettermark B, Brandt L, Kieler H, Bodén R
International journal of clinical practice 2014;68(1):104-10

Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region
Forslund T, Wettermark B, Wändell P, Von Euler M, Hasselström J, Hjemdahl P
European journal of clinical pharmacology 2014;70(12):1477-85

Selection bias in pharmacy-based patient surveys
Frisk P, Kälvemark-sporrong S, Wettermark B
Pharmacoepidemiology and drug safety 2014;23(2):128-39

Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment
Rydberg Dm, Holm L, Mejyr S, Loikas D, Schenck-gustafsson K, Von Euler M, et al
European journal of clinical pharmacology 2014;70(1):117-26

The Swedish Primary Care Cardiovascular Database (SPCCD): 74 751 hypertensive primary care patients
Hasselström J, Zarrinkoub R, Holmquist C, Hjerpe P, Ljungman C, Qvarnström M, et al
Blood pressure 2014;23(2):116-25

Utilization of triptans in Sweden; analyses of over the counter and prescription sales
Von Euler M, Keshani S, Baatz K, Wettermark B
Pharmacoepidemiology and drug safety 2014;23(12):1288-93

Changes in the utilization of venlafaxine after the introduction of generics in Sweden
Godman B, Persson M, Miranda J, Skiöld P, Wettermark B, Barbui C, et al
Applied health economics and health policy 2013;11(4):383-93

Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden
Loikas D, Wettermark B, Von Euler M, Bergman U, Schenck-gustafsson K
BMJ open 2013;3(5):-

Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model
Cars T, Wettermark B, Malmström Re, Ekeving G, Vikström B, Bergman U, et al
Basic & clinical pharmacology & toxicology 2013;112(6):392-400

High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health
Carlsson Ac, Wandell P, Osby U, Zarrinkoub R, Wettermark B, Ljunggren G
BMC PUBLIC HEALTH 2013;:670-

Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care
Andersson Ml, Böttiger Y, Lindh Jd, Wettermark B, Eiermann B
European journal of clinical pharmacology 2013;69(3):565-71

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries
Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström Re
International journal of clinical practice 2013;67(9):853-62

Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011
Wändell P, Carlsson Ac, Wettermark B, Lord G, Cars T, Ljunggren G
Family practice 2013;30(5):506-13

Persistence to antihypertensive drug treatment in Swedish primary healthcare
Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K, et al
European journal of clinical pharmacology 2013;69(11):1955-64

Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system
Forslund T, Wettermark B, Wändell P, Von Euler M, Hasselström J, Hjemdahl P
International journal of cardiology 2013;170(2):208-14

Socioeconomic status and the quality of prescribing asthma drugs in Sweden
Heibert Arnlind M, Wettermark B, Sjöborg B, Dahlén E, Loikas D, Wikström Jonsson E
The Journal of asthma : official journal of the Association for the Care of Asthma 2013;50(8):842-9

The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden
Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G, et al
European journal of heart failure 2013;15(9):995-1002

The intriguing future of pharmacoepidemiology
Wettermark B
European journal of clinical pharmacology 2013;69 Suppl 1():43-51

The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review
Wettermark B, Zoëga H, Furu K, Korhonen M, Hallas J, Nørgaard M, et al
Pharmacoepidemiology and drug safety 2013;22(7):691-9

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, et al
PLOS ONE 2013;8(11):e81208-

Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden
Piccinni C, Raschi E, Poluzzi E, Puccini A, Cars T, Wettermark B, et al
European journal of clinical pharmacology 2013;69(3):715-20

Validation of asthma and eczema in population-based Swedish drug and patient registers
Örtqvist Ak, Lundholm C, Wettermark B, Ludvigsson Jf, Ye W, Almqvist C
Pharmacoepidemiology and drug safety 2013;22(8):850-60

Adherence to guidelines for drug treatment of asthma in children: potential for improvement in Swedish primary care
Ingemansson M, Wettermark B, Jonsson Ew, Bredgard M, Jonsson M, Hedlin G, et al
Quality in primary care 2012;20(2):131-9

Antibiotics and asthma medication in a large register-based cohort study - confounding, cause and effect
Almqvist C, Wettermark B, Hedlin G, Ye W, Lundholm C
CLINICAL AND EXPERIMENTAL ALLERGY 2012;42(1):104-11

Antihypertensive treatment and control in a large primary care population of 21 167 patients Results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Qvarnstrom M, Wettermark B, Ljungman C, Zarrinkoub R, Hasselstrom J, Manhem K, et al
JOURNAL OF HUMAN HYPERTENSION 2011;25(8):484-91

[Big gender differences in drug utilization. The underlying disease is an insufficient explanation according to a systematic analysis]
Loikas D, Wettermark B, Von Euler M, Bergman U, Weitoft Gr, Schenck-gustafsson K
Lakartidningen 2011;108(40):1957-62

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs
Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 2011;11(1):121-9

European countries with small populations can obtain low prices for drugs: Lithuania as a case history
Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 2011;11(3):343-9

Policies to enhance prescribing efficiency in Europe: findings and future implications
Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al
FRONTIERS IN PHARMACOLOGY 2011;:141-

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009
Artis Study Grp, Neovius M, Sundstrom A, Simard Jf, Wettermark B, Cars T, et al
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2011;40(1):8-15

The 'Wise List' - A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm
Regional Drug Expert Consortium, Gustafsson Ll, Wettermark B, Godman B, Andersen-karlsson E, Bergman U, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2011;108(4):224-33

Usage, risk, and benefit of weight-loss drugs in primary care
Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B
Journal of obesity 2011;2011():459263-

[Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study]
Forslund T, Wettermark B, Raaschou P, Hjemdahl P, Krakau I
Lakartidningen 2010;107(13-14):910-3

Forecasting drug utilization and expenditure in a metropolitan health region
Regional Drug Expert Consortium, Wettermark B, Persson Me, Wilking N, Kalin M, Korkmaz S, et al
BMC HEALTH SERVICES RESEARCH 2010;:128-

Impact of restricted amoxicillin/clavulanic acid use on Escherichia coli resistance-antibiotic DU90% profiles with bacterial resistance rates: a visual presentation
Matanovic Sm, Bergman U, Vukovic D, Wettermark B, Vlahovic-palcevski V
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 2010;36(4):369-73

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren To, Kahan T
HEALTH POLICY 2010;94(3):221-9

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries
Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 2010;10(2):199-207

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications
Mcginn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 2010;10(1):73-85

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions
Mannheimer B, Wettermark B, Lundberg M, Pettersson H, Von Bahr C, Eliasson E
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2010;69(4):411-7

Regional variation and adherence to guidelines for drug treatment of asthma
Arnlind Mh, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson Ew
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(2):187-98

The Nordic Countries as a Cohort for Pharmacoepidemiological Research
Furu K, Wettermark B, Andersen M, Martikainen Je, Almarsdottir Ab, Sorensen Ht
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2010;106(2):86-94

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al
Pharmaceuticals (Basel, Switzerland) 2010;3(8):2470-2494

A method to include the environmental hazard in drug prescribing
Castensson S, Eriksson V, Lindborg K, Wettermark B
PHARMACY WORLD & SCIENCE 2009;31(1):24-31

Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care
Wettermark B, Pehrsson A, Juhasz-haverinen M, Veg A, Edlert M, Törnwall-bergendahl G, et al
Quality in primary care 2009;17(3):179-89

[Fully possible to reduce the costs of hypertension treatment]
Wettermark B, Angman A, Hjemdahl P
Lakartidningen 2009;106(23):1558-62

How Drug-Drug Interactions Related to Serotonin Reuptake Inhibitors Affect Drug Dispensing: A Population-Based Study
Mannheimer B, Wettermark B, Lundberg M, Pettersson H, Von Bahr C, Eliasson E
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2009;:S242-S242

HOW DRUG-DRUG INTERACTIONS RELATED TO SEROTONIN REUPTAKE INHIBITORS AFFECT DRUG DISPENSING: A POPULATION-BASED STUDY
Mannheimer B, Wettermark B, Lundberg M, Pettersson H, Von Bahr C, Eliasson E
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:68-69

Impact of Recent European Reforms To Encourage Prescribing of Generic Statins
Wettermark B, Godman B, Martikainen J, Samavarchi Ag, Palcevski Vv
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2009;:S147-S147

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future
Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P
Expert review of pharmacoeconomics & outcomes research 2009;9(5):475-84

IMPACT OF REFORMS TO ENHANCE THE QUALITY AND EFFICIENCY OF STATIN PRESCRIBING ACROSS 20 EUROPEAN COUNTRIES
Godman B, Wettermark B, Vlahovic-palcevski V, Schwabe U, Gulbinovic J, Laius O, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:35-35

IMPACT OF THE DRUG-DRUG INTERACTION DATABASE SFINX ON THE PREVALENCE OF CLINICALLY RELEVANT DRUG INTERACTIONS
Andersson Ml, Eiermann B, Wettermark B, Bottiger Y
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:138-138

Improving the Quality and Efficiency of Drug Prescribing in Primary Care by Means of Financial Incentives
Wettermark B, Pehrsson A, Juhasz-haverinen M, Veg A, Edlert M, Tornwall-bergendahl G, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2009;:S261-S261

Increasing Prevalence and Incidence of Drug Use in Sweden-Data from the National Prescribed Drug Register
Leimanis A, Ericsson O, Fored M, Hammar N, Wettermark B
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2009;:S60-S60

[Lower and lower cholesterol targets increase adverse effects]
Stockholms Iäns Landsting, Forfattarna Utgör Läkemedelssakkunnigas (läksak) Expert-grupp För Hjärt-kärlsjukdomar, Hjemdahl P, Allhammar A, Heaton C, Hulting J, et al
Lakartidningen 2009;106(40):2550-1

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance
Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson Ll
Expert review of pharmacoeconomics & outcomes research 2009;9(1):65-83

Potential savings without compromising the quality of care
Norman C, Zarrinkoub R, Hasselstrom J, Godman B, Granath F, Wettermark B
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 2009;63(9):1320-6

[Rational introduction to new drugs requires both a health care and a community perspective]
Gustafsson Ll, Wettermark B, Kalin M, Korkmaz S, Persson Me, Almkvist H, et al
Lakartidningen 2009;106(1-2):52-

[SBU should investigate what is an evidence-based and cost-effective use of statins]
Hjemdahl P, Allhammar A, Heaton C, Hulting J, Kahan T, Malmström R, et al
Lakartidningen 2009;106(32-33):1992-4

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences
Wettermark B, Godman B, Jacobsson B, Haaijer-ruskamp Fm
Applied health economics and health policy 2009;7(3):137-47

Substantial Differences in Utilization and Expenditures of PPI across Europe
Godman B, Palcevski Vv, Samavarchi Ag, Bergman U, Wettermark B
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2009;:S238-S238

TRENDS IN CONSUMPTION AND EXPENDITURE OF PROTON PUMP INHIBITORS (PPIS) IN 20 EUROPEAN COUNTRIES
Godman B, Vlahovic-palcevski V, Laius O, Bennett K, Gulbinovic J, Diogene E, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:37-37

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs
Godman B, Schwabe U, Selke G, Wettermark B
PHARMACOECONOMICS 2009;27(5):435-8

Diffusion of interferon beta in Iran and its utilization in Tehran
Palesh M, Jonsson Pm, Jamshidi H, Wettermark B, Tomson G, Fredrikson S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2008;17(9):934-41

Dispensed volumes of anti-asthmatic drugs related to the prevalence of asthma and COPD in Sweden
Haupt D, Wettermark B, Nilsson Jlg
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2008;17(5):461-7

Enhancing the rational use of new medicines across European health care systems
Piperska Grp, Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(12):1137-8

[Quality reports reduce drug costs in primary health care. Stockholm County Council a model for decentralized expenditure responsibility]
Almkvist H, Bergman U, Edlert M, Juhasz-haverinen M, Pehrsson A, Bergen-dahl Gt, et al
Lakartidningen 2008;105(42):2930-4

Quality use of medicines: A new method of combining antibiotic consumption and sensitivity data - application in a Russian hospitals
Goryachkina K, Babak S, Burbello A, Wettemark B, Bergman U
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2008;17(6):636-44

Recent national and regional drug reforms in Sweden - Implications for pharmaceutical companies in Europe
Wettermark B, Godman B, Andersson K, Gustafsson Ll, Haycox A, Bertele V
PHARMACOECONOMICS 2008;26(7):537-50

Secondary prevention in a large stroke population - A study of patients' purchase of recommended drugs
Wettermark B, Persson A, Von Euler M
STROKE 2008;39(10):2880-5

Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines
Frisk P, Mellgren To, Hedberg N, Berlin A, Granath F, Wettermark B
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(12):1223-9

Prevalence and incidence of drug use in Sweden 18 months data from the new national prescribed drug register
Fored M, Hammar N, Leimanis A, Olausson Po, Wettermark B
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2007;:S95-S95

The new Swedish Prescribed Drug Register - Opportunities for pharmacoepidemiological research and experience from the first six months
Wettermark B, Harnmar N, Michaelfored C, Leimanis A, Olausson Po, Bergman U, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2007;16(7):726-35

A new register on prescribed pharmaceuticals in Sweden
Leimanis A, Wettermark B, Hammar N, Fored M, Olausson Po, Rosen M
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2006;:S217-S217

How can prescribing quality indicators improve public health
Haaijer-ruskamp Fm, Avery Tj, Avorn J, Wettermark B
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2006;:S37-S37

Population based drug databases in sweden: How representative is the county of Jamtland as a source of data in Sweden?
Bergman U, Leimanis A, Lundberg M, Wettermark B
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2006;:S185-S185

[Quality indicators for drug prescribing--the situation in Sweden]
Wettermark B, Tomson G, Bergman U
Lakartidningen 2006;103(46):3607-11

Using aggregate data on dispensed drugs to evaluate the quality of prescribing in urban primary health care in Sweden
Wettermark B, Bergman U, Krakau I
PUBLIC HEALTH 2006;120(5):451-61

A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists
Wettermark B, Haglund K, Gustafsson Ll, Persson Pm, Bergman U
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2005;14(8):579-88

Attitudes to feedback with drug utilisation 90% (DU90%) profiles among prescribers in Rijeka, Croatia
Vlahovic-palcevski V, Wettermark B, Prpic I, Bergman U
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2004;13(10):725-7

Drug utilisation 90% profiles - a useful tool for quality assessment of prescribing in primary health care in Stockholm
Wettermark B, Pehrsson A, Jinnerot D, Bergman U
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2003;12(6):499-510

Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm)
Vlahovic-palcevski V, Wettermark B, Bergman U
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2002;58(3):209-14

[Can we afford good cholesterol lowering therapy? Budgeting of statin costs versus medical needs in the county of Stockholm]
Wettermark B, Hjemdahl P
Lakartidningen 2001;98(48):5472-3

[Feedback on prescribing profiles at a primary health center. Important element in quality assurance of drug prescription]
Nyman K, Bergens A, Björin As, Guterstam P, Nyrén O, Jansson U, et al
Lakartidningen 2001;98(3):160-4

Marked differences in antibiotic use and resistance between University hospitals in Vilnius, Lithuania, and Huddinge, Sweden
Gulbinovic J, Myrback Ke, Bytautiene J, Wettermark B, Struwe J, Bergman U
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE 2001;7(4):383-9

Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions
Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2000;56(3):269-72

Psychotropic drug use in non-psychiatric departments of three European university hospitals
Llerena A, Kiivet Ra, Dahl Ml, Vega Js, Rootslane L, Wettermark B
NORDIC JOURNAL OF PSYCHIATRY 2000;54(1):61-65

Antibiotic use in 3 European university hospitals
Kiivet Ra, Dahl Ml, Llerena A, Maimets M, Wettermark B, Berecz R
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1998;30(3):277-80

Drug utilization 90% - a simple method for assessing the quality of drug prescribing
Bergman U, Popa C, Tomson Y, Wettermark B, Einarson Tr, Aberg H, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 1998;54(2):113-8

Visa alla publikationer